Decision Resources projects peak sales for three HIV drugs
WALTHAM, Mass. Three new drugs for treating HIV from Gilead Sciences and J&J subsidiary Tibotec could have combined peak-year sales in the billions of dollars in several developed countries, according to a report by market research firm Decision Resources.
The report, titled “Human Immunodeficiency Virus,” predicted that through 2018, Gilead’s Quad, Tibotec’s rilpivirine and the combined drug rilpivirine, emtricitabine and tenofovir, made by Gilead and Tibotec, will have sales of more than $5 billion in the United States, United Kingdom, Germany, Italy, Spain and Japan.
“Gilead and Tibotec continue to make strong progress with their HIV programs,” Decision Resources therapeutic area director Danielle Dratyon said. “Gilead will bring the first-ever quadruple fixed-dose therapy — Quad — to the market, and Tibotec will bring a novel NNRTI — rilpivirine — to the market by 2011.”
Crown Crafts acquires Bibsters product from P&G
GONZALES, La. Crown Crafts has acquired a disposable bib product from Procter & Gamble, the company announced last week.
Crown Crafts said its subsidiary Hamco now will manufacture and distribute Bibsters products, a disposable bib that provides coverage for infants and toddlers while feeding, which was introduced by P&G in 2003. Hamco also acquired the inventory associated with the Bibsters product line and plans to integrate the distribution of the Bibsters product line into the Company’s facilities in Compton, Calif.
“We are thrilled to find an opportunity that will complement last year’s acquisition of Neat Solutions by expanding our business in the disposable products category,” said E. Randall Chestnut, chairman, president and CEO. “Hamco already has the overwhelming market share in reusable bibs, and we are confident that the Bibsters line of disposable bibs will solidify Hamco’s position as the overall leader in infant and toddler bibs.”
FDA to review Orexigen’s obesity treatment
SAN DIEGO The Food and Drug Administration has accepted a new drug application from a biopharmaceutical company focused on the treatment of obesity.
Orexigen said its investigational obesity treatment Contrave (naltrexone SR/bupropion SR), which addresses both physiological and behavioral drivers of the disease, was accepted by the FDA, following its Contrave Obesity Research clinical program, which included more than 4,500 patients.
“We are pleased the FDA has accepted our NDA for filing and look forward to working with the agency during the review process,” said Michael Narachi, Orexigen president and CEO. “If approved, we believe Contrave will become an important therapeutic option for obese patients, making weight loss and weight maintenance an achievable cornerstone in the treatment of obesity and its common co-morbidities.”